세계의 RNA 분석 시장 규모, 점유율, 동향 분석 보고서 : 제품별(키트&시약, 서비스, 기기), 기술별(qPCR, 마이크로어레이, 시퀀스), 용도별, 최종 용도별, 부문 동향(2023-2030년)

RNA Analysis Market Growth & Trends

The global RNA analysis market size is expected to reach USD 20.21 billion by 2030, registering a CAGR of 10.86% according to a new report by Grand View Research, Inc.. Transcriptomics is one of the most advanced fields in the post-genomic period. Technological advancements in this industry can be attributed to the increasing applications of transcriptome sequencing in life science for capturing polyadenylated RNA. With the expansion of next-generation high-throughput sequencing technology, the analysis of transcriptomes has been gradually improving the understanding of the regulatory network of RNA-based genes. For instance, in July 2021, the Lithuanian team is developing a droplet-based technique for simultaneous mRNA and microRNA capture and sequencing in a single cell.

The European Union backs the research with a USD174,000 Horizon 2020 research grant. Ribonucleic acid transcriptome analysis enables researchers to analyze the position of genes as well as the functional patterns of a specific gene in an organism. The method assists in evaluating every transcript's changing behavior at the development stage and assesses all the elements of a transcript, including messenger ribonucleic acid, non-coding ribonucleic acid, and micro ribonucleic acid, for identifying the transcriptional structure of genes.

The growing need for analyzing a huge number of genes to understand the gene-to-drug interactions is anticipated to enhance the application of transcriptomics technologies in discovery applications and drug development. For instance, transcriptome profiles of COVID-19 patients have been analyzed to examine the disease prognosis and management. Furthermore, increasing demand for personalized medicines is anticipated to fuel the industry growth during the forecast period. In April 2020, Caris Life Sciences announced the submission of Pre-Market Approval applications for MI Transcriptome CDx to the USFDA. It is a powerful precision medicine assay, which contains significant companion diagnostic biomarkers. On the other hand, data management in transcriptomic research and the lack of effective bioinformatics tools are some of the major challenges in the industry.

The evolution of high-throughput technologies has provided invaluable opportunities for generating holistic views of complex biological processes. Despite the considerable availability of omics data, the conversation of biological data into clinically valuable knowledge remains one of the major challenges. It is not only because of insufficient current data processing or integration methods but also for inappropriate application of existing analysis approaches. North America has been reported as the highest revenue-generating region in 2021 owing to increasing investments in pharmaceutical and biotechnology research by corporations. Asia Pacific is projected to register the fastest CAGR from 2022 to 2030 owing to the low-cost manufacturing services.

RNA Analysis Market Report Highlights

• Real-Time- PCR (qPCR) accounted for the major market share in the technology segment in 2022 and is said to continue the trend during the forecast period owing to the increasing use of PCR for COVID-19 diagnostic across the globe
• The transcriptome sequencing technology is estimated to register a significant CAGR during the forecast period owing to factors, such as advancements in sequencing technology and growing acceptance of NGS technology
• The kits and reagents segment accounted for the highest revenue share in 2022 owing to a high utilization rate of consumables during transcriptomic studies
• The infectious diseases and pathogenesis segment accounted for the largest share in 2022 and is anticipated to have a similar trend during the forecasted period
• The increasing prevalence of the infectious disease is the major factor driving the segment growth
• Government institutes & academic centers dominated the end-user segment as the increasing number of institutes and centers leveraged high throughput technologies for the effective and efficient process of ribonucleic acid analysis

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Information Analysis
  • 1.2.2. Market Formulation & Data Visualization
  • 1.2.3. Data Validation & Publishing
• 1.3. Research Assumptions
• 1.4. Information Procurement
  • 1.4.1. Primary Research
• 1.5. Information or Data Analysis
• 1.6. Market Formulation & Validation
• 1.7. Market Model
• 1.8. Global Market: CAGR Calculation
• 1.9. Objectives
  • 1.9.1. Objective 1:
  • 1.9.2. Objective 2:

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing Demand for Transcriptomics in Cancer Personalized/Precision Medicine
    • 3.2.1.2. Rising Diagnostic Utility Of Transcriptomics Technologies
    • 3.2.1.3. Advent of Novel Approaches for Understanding Gene Expression at RNA Level
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Higher Cost of Research & Developments
    • 3.2.2.2. High Costs Associated With Analysis Platforms
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Product Business Analysis

• 4.1. RNA Analysis Market: Product Movement Analysis
• 4.2. Instruments
  • 4.2.1. Instruments Market, 2018 - 2030 (USD Million)
• 4.3. Kits & Reagents
  • 4.3.1. Kits & Reagents Market, 2018 - 2030 (USD Million)
  • 4.3.2. miRNA & siRNA
    • 4.3.2.1. miRNA & siRNA Market, 2018 - 2030 (USD Million)
  • 4.3.3. Reverse Transcriptases & RT-PCR
    • 4.3.3.1. Reverse Transcriptases & RT-PCR Market, 2018 - 2030 (USD Million)
  • 4.3.4. RNA Extraction & Purification
    • 4.3.4.1. RNA Extraction & Purification Market, 2018 - 2030 (USD Million)
  • 4.3.5. RNA Interference
    • 4.3.5.1. RNA Interference Market, 2018 - 2030 (USD Million)
  • 4.3.6. Others
    • 4.3.6.1. Other Kits & Reagents Market, 2018 - 2030 (USD Million)
• 4.4. Services
  • 4.4.1. Services Market, 2018 - 2030 (USD Million)

Chapter 5. Technology Business Analysis

• 5.1. RNA Analysis Market: Technology Movement Analysis
• 5.2. Real Time-PCR (qPCR)
  • 5.2.1. Real Time-PCR (qPCR) Market, 2018 - 2030 (USD Million)
• 5.3. Microarray
  • 5.3.1. Microarray Market, 2018 - 2030 (USD Million)
• 5.4. Sequencing
  • 5.4.1. Sequencing Market, 2018 - 2030 (USD Million)
• 5.5. Others
  • 5.5.1. Other Technologies Market, 2018 - 2030 (USD Million)

Chapter 6. Application Business Analysis

• 6.1. RNA Analysis Market: Application Movement Analysis
• 6.2. Construction of RNA Expression Atlas
  • 6.2.1. Construction of RNA Expression Atlas Market, 2018 - 2030 (USD Million)
• 6.3. Epigenetics
  • 6.3.1. Epigenetics Market, 2018 - 2030 (USD Million)
• 6.4. Infectious Diseases & Pathogenesis
  • 6.4.1. Infectious Diseases & Pathogenesis Market, 2018 - 2030 (USD Million)
• 6.5. Alternative RNA Splicing
  • 6.5.1. Alternative RNA Splicing Market, 2018 - 2030 (USD Million)
• 6.6. RNA Structure & Molecular Dynamics
  • 6.6.1. RNA Structure & Molecular Dynamics Market, 2018 - 2030 (USD Million)
• 6.7. Development & Delivery of RNA Therapeutics
  • 6.7.1. Development & Delivery of RNA Therapeutics Market, 2018 - 2030 (USD Million)
• 6.8. Others
  • 6.8.1. Other Applications Market, 2018 - 2030 (USD Million)

Chapter 7. End-Use Business Analysis

• 7.1. Government Institutes & Academic Centers
  • 7.1.1. Government Institutes & Academic Centers Market, 2018 - 2030 (USD Million)
• 7.2. Pharmaceutical & Biotechnology Companies
  • 7.2.1. Pharmaceutical & Biotechnology Companies Market, 2018 - 2030 (USD Million)
• 7.3. Hospitals & Clinics
  • 7.3.1. Hospitals & Clinics Market, 2018 - 2030 (USD Million)
• 7.4. Contract Research Organizations (CROs)
  • 7.4.1. Contract Research Organizations (CROs) Market, 2018 - 2030 (USD Million)

Chapter 8. Regional Business Analysis

• 8.1. RNA Analysis Market Share By Region, 2022 & 2030
• 8.2. North America
  • 8.2.1. North America RNA Analysis Market, 2018 - 2030 (USD Million)
  • 8.2.2. U.S.
    • 8.2.2.1. Key Country Dynamics
    • 8.2.2.2. Target Disease Prevalence
    • 8.2.2.3. Competitive Scenario
    • 8.2.2.4. U.S. RNA Analysis Market, 2018 - 2030 (USD Million)
  • 8.2.3. Canada
    • 8.2.3.1. Key Country Dynamics
    • 8.2.3.2. Target Disease Prevalence
    • 8.2.3.3. Competitive Scenario
    • 8.2.3.4. Canada RNA Analysis Market, 2018 - 2030 (USD Million)
• 8.3. Europe
  • 8.3.1. Europe RNA Analysis Market, 2018 - 2030 (USD Million)
  • 8.3.2. UK
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Target Disease Prevalence
    • 8.3.2.3. Competitive Scenario
    • 8.3.2.4. UK RNA Analysis Market, 2018 - 2030 (USD Million)
  • 8.3.3. Germany
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Target Disease Prevalence
    • 8.3.3.3. Competitive Scenario
    • 8.3.3.4. Germany RNA Analysis Market, 2018 - 2030 (USD Million)
  • 8.3.4. France
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Target Disease Prevalence
    • 8.3.4.3. Competitive Scenario
    • 8.3.4.4. France RNA Analysis Market, 2018 - 2030 (USD Million)
  • 8.3.5. Italy
    • 8.3.5.1. Key Country Dynamics
    • 8.3.5.2. Target Disease Prevalence
    • 8.3.5.3. Competitive Scenario
    • 8.3.5.4. Italy RNA Analysis Market, 2018 - 2030 (USD Million)
  • 8.3.6. Spain
    • 8.3.6.1. Key Country Dynamics
    • 8.3.6.2. Target Disease Prevalence
    • 8.3.6.3. Competitive Scenario
    • 8.3.6.4. Spain RNA Analysis Market, 2018 - 2030 (USD Million)
  • 8.3.7. Denmark
    • 8.3.7.1. Key Country Dynamics
    • 8.3.7.2. Target Disease Prevalence
    • 8.3.7.3. Competitive Scenario
    • 8.3.7.4. Denmark RNA Analysis Market, 2018 - 2030 (USD Million)
  • 8.3.8. Sweden
    • 8.3.8.1. Key Country Dynamics
    • 8.3.8.2. Target Disease Prevalence
    • 8.3.8.3. Competitive Scenario
    • 8.3.8.4. Sweden RNA Analysis Market, 2018 - 2030 (USD Million)
  • 8.3.9. Norway
    • 8.3.9.1. Key Country Dynamics
    • 8.3.9.2. Target Disease Prevalence
    • 8.3.9.3. Competitive Scenario
    • 8.3.9.4. Norway RNA Analysis Market, 2018 - 2030 (USD Million)
• 8.4. Asia Pacific
  • 8.4.1. Asia Pacific RNA Analysis Market, 2018 - 2030 (USD Million)
  • 8.4.2. Japan
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Target Disease Prevalence
    • 8.4.2.3. Competitive Scenario
    • 8.4.2.4. Japan RNA Analysis Market, 2018 - 2030 (USD Million)
  • 8.4.3. China
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Target Disease Prevalence
    • 8.4.3.3. Competitive Scenario
    • 8.4.3.4. China RNA Analysis Market, 2018 - 2030 (USD Million)
  • 8.4.4. India
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Target Disease Prevalence
    • 8.4.4.3. Competitive Scenario
    • 8.4.4.4. India RNA Analysis Market, 2018 - 2030 (USD Million)
  • 8.4.5. Australia
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Target Disease Prevalence
    • 8.4.5.3. Competitive Scenario
    • 8.4.5.4. Australia RNA Analysis Market, 2018 - 2030 (USD Million)
  • 8.4.6. Thailand
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Target Disease Prevalence
    • 8.4.6.3. Competitive Scenario
    • 8.4.6.4. Thailand RNA Analysis Market, 2018 - 2030 (USD Million)
  • 8.4.7. South Korea
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Target Disease Prevalence
    • 8.4.7.3. Competitive Scenario
    • 8.4.7.4. South Korea RNA Analysis Market, 2018 - 2030 (USD Million)
• 8.5. Latin America
  • 8.5.1. Latin America RNA Analysis Market, 2018 - 2030 (USD Million)
  • 8.5.2. Brazil
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Target Disease Prevalence
    • 8.5.2.3. Competitive Scenario
    • 8.5.2.4. Brazil RNA Analysis Market, 2018 - 2030 (USD Million)
  • 8.5.3. Mexico
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Target Disease Prevalence
    • 8.5.3.3. Competitive Scenario
    • 8.5.3.4. Mexico RNA Analysis Market, 2018 - 2030 (USD Million)
  • 8.5.4. Argentina
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Target Disease Prevalence
    • 8.5.4.3. Competitive Scenario
    • 8.5.4.4. Argentina RNA Analysis Market, 2018 - 2030 (USD Million)
• 8.6. MEA
  • 8.6.1. MEA RNA Analysis Market, 2018 - 2030 (USD Million)
  • 8.6.2. South Africa
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Target Disease Prevalence
    • 8.6.2.3. Competitive Scenario
    • 8.6.2.4. South Africa RNA Analysis Market, 2018 - 2030 (USD Million)
  • 8.6.3. Saudi Arabia
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Target Disease Prevalence
    • 8.6.3.3. Competitive Scenario
    • 8.6.3.4. Saudi Arabia RNA Analysis Market, 2018 - 2030 (USD Million)
  • 8.6.4. UAE
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Target Disease Prevalence
    • 8.6.4.3. Competitive Scenario
    • 8.6.4.4. UAE RNA Analysis Market, 2018 - 2030 (USD Million)
  • 8.6.5. Kuwait
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Target Disease Prevalence
    • 8.6.5.3. Competitive Scenario
    • 8.6.5.4. Kuwait RNA Analysis Market, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Share Analysis, 2022
• 9.4. Company Profiles/Listing
  • 9.4.1. Agilent Technologies, Inc
    • 9.4.1.1. Overview
    • 9.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.1.3. Product Benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. F. Hoffmann-La Roche AG
    • 9.4.2.1. Overview
    • 9.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.2.3. Product Benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. Illumina, Inc.
    • 9.4.3.1. Overview
    • 9.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.3.3. Product Benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. QIAGEN
    • 9.4.4.1. Overview
    • 9.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.4.3. Product Benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. Thermo Fisher Scientific, Inc.
    • 9.4.5.1. Overview
    • 9.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.5.3. Product Benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. Eurofins Scientific
    • 9.4.6.1. Overview
    • 9.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.6.3. Product Benchmarking
    • 9.4.6.4. Strategic Initiatives
  • 9.4.7. Merck KGaA
    • 9.4.7.1. Overview
    • 9.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.7.3. Product Benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. Bio-Rad Laboratories, Inc.
    • 9.4.8.1. Overview
    • 9.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.8.3. Product Benchmarking
    • 9.4.8.4. Strategic Initiatives
  • 9.4.9. Pacific Bioscience of California, Inc.;
    • 9.4.9.1. Overview
    • 9.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.9.3. Product Benchmarking
    • 9.4.9.4. Strategic Initiatives
  • 9.4.10. Affymetrix, Inc.
    • 9.4.10.1. Overview
    • 9.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.10.3. Product Benchmarking
    • 9.4.10.4. Strategic Initiatives
  • 9.4.11. Danaher
    • 9.4.11.1. Overview
    • 9.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.11.3. Product Benchmarking
    • 9.4.11.4. Strategic Initiatives
  • 9.4.12. Promega
    • 9.4.12.1. Overview
    • 9.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.12.3. Product Benchmarking
    • 9.4.12.4. Strategic Initiatives